6 unknown, 4 completed, 3 terminated, 1 active not recruiting. 11 Phase 1, 7 Phase 2, 2 Phase 3.
Follow SHR3162: new trials by email Literature Review of SHR3162 trials Research Report on SHR3162
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 496 | 2021-03-18 | 2024-12-31 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer Fluzoparib - Pancreatic Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 74 | 2020-12-17 | 2020-12-31 |
| A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Fluzoparib, Placebo - Metastatic Pancreatic Cancer | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 5 | 2020-08-19 | 2024-03-28 |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） Fluzoparib, Apatinib - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2020-07-01 | 2020-12-09 |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer SHR7390, Famitinib, SHR3162 - Breast Cancer, Metastatic Cancer | Phase 2 | Unknown | Fudan University | 319 | 2020-05-01 | 2022-07-26 |
| A Trial of SHR3162 in Healthy Caucasian Volunteers SHR3162 - Healthy Volunteers | Phase 1 | Completed | Atridia Pty Ltd. | 12 | 2020-04-17 | 2022-07-14 |
| Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects SHR3162 - Healthy Adult Male and Female Volunteers | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2020-04-10 | 2020-04-10 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer Fluzoparib, Fluzoparib placebo, mFOLFIRINOX - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 39 | 2020-01-21 | 2024-08-16 |
| A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC SHR3680, SHR3162, SHR3680(Placebo) - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2019-04-08 | 2025-06-24 |
| FUSCC Refractory TNBC Umbrella (FUTURE) Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel - Triple-negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 140 | 2018-10-18 | 2022-08-10 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors SHR7390, SHR-1210, SHR3162 - Solid Tumor | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 31 | 2017-07-24 | 2022-09-01 |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients Fluzoparib, Apatinib - Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 98 | 2017-03-09 | 2022-07-01 |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients Fluzoparib, Apatinib, Paclitaxel - Recurrent and Metastatic Gastric Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2017-01-01 | 2017-03-07 |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors SHR3162 - Neoplasm, Solid Tumors | Phase 1 | Completed | Atridia Pty Ltd. | 30 | 2016-06-01 | 2019-09-19 |
Breast Neoplasms (2) · Pancreatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (9) · Fudan University (3) · Atridia Pty Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Tianjin Medical University Second Hospital (1)
China (12) · Australia (3) · Belgium (1) · Czechia (1) · France (1) · Hungary (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Boyong Shen, M.D. (1) · Haitao Wang (1) · RuiHua Xu, MD, PhD (1) · Xianjun Yu, M.D. (1) · Yupei Zhao, Ph.D (1) · Zhi-Ming Shao (1) · Zhimin U Shao, Professor (1)
PMID 32719455, PMID 33570247, PMID 35105939, PMID 37775744, PMID 38290515, PMID 39232761